Skip to main content

Advertisement

Table 7 Strict OMERACT-OARSI responder analysis

From: Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial

Group 13 Weeks n (%) 26 Weeks n (%)
Synvisc-One 17 (53) 19 (59)
Hydros 21 (66) 22 (69)
Hydros-TA 24 (71) 22 (65)